Chimeric Therapeutics announces breakthrough AML response with CHM CORE-NK in Phase 1B trial
Chimeric Therapeutics has reported a significant milestone in its ongoing clinical trials, wherein a patient diagnosed with Acute Myelogenous Leukemia (AML) has exhibited a complete response following treatment in the CHM CORE-NK + Vactosertib Phase 1b trial. This achievement marks a cancer treatment innovation, highlighting immunotherapy progress and a significant cell therapy milestone. Chimeric Therapeutics, […]